Dare Bioscience logo
DAREDare Bioscience
Trade DARE now
Dare Bioscience primary media

About Dare Bioscience

Dare Bioscience (NASDAQ:DARE) is a biopharmaceutical company focused on women's reproductive health. By advancing innovative products for women, Dare aims to improve their well-being across various life stages, addressing needs in contraception, vaginal health, fertility, and sexual health. The company's diverse portfolio includes clinical-stage drug projects designed to provide better treatment options and enhance quality of life. Through research and partnerships, Dare Bioscience is committed to delivering groundbreaking therapies that can fulfill unmet medical needs for women around the globe, thereby achieving its mission to revolutionize women's healthcare.

What is DARE known for?

Snapshot

Public US
Ownership
2005
Year founded
25
Employees
San Diego, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
San Diego, US

Products and/or services of Dare Bioscience

  • Ovaprene, a non-hormonal, monthly contraceptive designed to provide a mixture of spermicides within a vaginal ring.
  • Sildenafil Cream, 3.6%, a novel topical treatment aimed at enhancing female sexual arousal by increasing blood flow.
  • XACIATO (Clindamycin Phosphate Vaginal Gel, 2%), developed for the treatment of bacterial vaginosis in female patients.
  • DARE-HRT1, a bioidentical combination of estradiol and progesterone in a single, intravaginal ring for hormone therapy.
  • DARE-FRT1, targeting the development of a formulation for ovarian hormone replacement therapy in women suffering from premature ovarian insufficiency.
  • DARE-RH1, an investigational nasal spray for the treatment of reproductive health issues, leveraging a novel delivery system.

Dare Bioscience executive team

  • Ms. Sabrina Martucci JohnsonCEO, President, Principal Financial Officer, Secretary & Director
  • Ms. MarDee J. Haring-LaytonChief Accounting Officer
  • Mr. Mark WaltersVice President of Operations
  • Dr. David Friend Ph.D.Chief Scientific Officer
  • Jennifer KiangVice President of Corporate Affairs & Development

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.